Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?. (April 2019)

• Record Type: Journal Article
• Authors: Dasanu, Constantin A; Samara, Yazeed; Codreanu, Ion; Limonadi, Farhad M; Hamid, Omid; Alvarez-Argote, Juliana
• Is Part Of: Journal of oncology pharmacy practice. Volume 25:Number 3(2019)
• Page Start: 638
• Page End: 647
• Publication Date: 2019-04
• Subjects: Angiogenesis -- bevacizumab -- peritumoral brain edema -- relapsed/refractory meningioma -- vascular endothelial growth factor/receptor pathway; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155218799850
• Languages: English
• ISSNs: 1078-1552

Abstract

Effective therapies for relapsed/refractory meningioma after surgery and radiation therapy represent an unmet need. Most meningiomas are highly vascularized tumors and, therefore, potentially amenable to antiangiogenic therapy. Herein, we review comprehensively the scientific literature on systemic therapy options for relapsed, persistent or metastatic meningioma, not amenable to local therapy. Also, this review offers insights into the function of vascular endothelial growth factor/receptor pathway both in health and disease. Further, we address the current status of the preclinical and clinical studies targeting vascular endothelial growth factor/receptor signaling in meningioma. Most relevant publications were identified through searching the PubMed/Medline database for articles published from inception to 1 February 2018. Vascular endothelial growth factor pathway activation might represent the primary driver of angiogenesis in meningioma. Positive findings of two prospective phase II trials, supported by the results of several retrospective cohorts, suggest a clinical benefit for the vascular endothelial growth factor inhibitor bevacizumab in refractory meningioma. Bevacizumab causes both peritumoral brain edema reduction and true meningioma shrinkage. Patients with WHO grades II–III meningioma appear to benefit more than patients with grade I disease. Similarly, responses have been documented with certain oral targeted anti-vascular endothelial growth factor/receptor agents. Further exploration of the role of vascular endothelial growth factor/receptor inhibitors in refractory meningioma seems warranted.